{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:32:15Z","timestamp":1789014735702,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101132","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:10:22Z","timestamp":1694232622000},"page":"101132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-2171","authenticated-orcid":false,"given":"Alessandro","family":"Bosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-9944","authenticated-orcid":false,"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5289","authenticated-orcid":false,"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0005","first-page":"293","article-title":"Testosterone-induced remission in aplastic anemia","volume":"98","author":"Nt","year":"1959","journal-title":"AMA J Diseases Child"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/edrv-8-1-1","article-title":"Biological actions of androgens","volume":"8","author":"Mooradian","year":"1987","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.blre.2023.101132_bb0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0149-2918(01)80070-9","article-title":"Review of oxymetholone: a 17\u03b1-alkylated anabolic-androgenic steroid","volume":"23","author":"Pavlatos","year":"2001","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.blre.2023.101132_bb0020","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0149-2918(01)80114-4","article-title":"A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids","volume":"23","author":"Shahidi","year":"2001","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0002-9378(81)90611-6","article-title":"Danazol: endocrine pharmacology and therapeutic applications","volume":"141","author":"Barbieri","year":"1981","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0030","first-page":"147","article-title":"Treatment of endometriosis with an antigonadotropin, Danazol. A laparoscopic and histologic evaluation","volume":"46","author":"Dmowski","year":"1975","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0015-0282(16)48431-1","article-title":"Treatment of endometriosis with danazol: report of a 6-year prospective study","volume":"43","author":"Buttram","year":"1985","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0040","first-page":"85","article-title":"A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease","volume":"5","author":"Gorins","year":"1984","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101132_bb0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.2020006481","article-title":"Inherited bone marrow failure in the pediatric patient","volume":"140","author":"Dokal","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101132_bb0050","first-page":"2236","article-title":"Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells","volume":"114","author":"Calado","year":"2009","journal-title":"Blood, J American Soc Hematol"},{"issue":"19","key":"10.1016\/j.blre.2023.101132_bb0055","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.3390\/ijms21197196","article-title":"Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita","volume":"21","author":"Vieri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.2047-2927.2012.00009.x","article-title":"Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men","volume":"1","author":"Maggio","year":"2013","journal-title":"Andrology."},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0065","first-page":"4467","article-title":"Effect of testosterone and hypoxia on the expansion of umbilical cord blood CD34+ cells in vitro","volume":"14","author":"Zhou","year":"2017","journal-title":"Exp Ther Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101132_bb0070","first-page":"2289","article-title":"Human megakaryocytes and platelets contain the estrogen receptor \u03b2 and androgen receptor (AR): testosterone regulates AR expression","volume":"95","author":"Khetawat","year":"2000","journal-title":"Blood, J American Soc Hematol"},{"key":"10.1016\/j.blre.2023.101132_bb0075","article-title":"Haematological actions of androgens","volume":"1","author":"Warren","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.blre.2023.101132_bb0080","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/ph15111377","article-title":"Danazol in refractory autoimmune hemolytic Anemia or immune thrombocytopenia: a case series report and literature review","volume":"15","author":"Huang","year":"2022","journal-title":"Pharmaceuticals."},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0085","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00277-011-1163-x","article-title":"Danazol as first-line therapy for aplastic anemia","volume":"90","author":"Jaime-P\u00e9rez","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101132_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/JBM.S383148","article-title":"Efficacy of Oxymetholone in severe and nonsevere acquired aplastic Anemia: a propensity score matching analysis","volume":"1","author":"Pengthina","year":"2022","journal-title":"J Blood Medicine"},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ajh.21118","article-title":"Danazol therapy for aplastic anemia refractory to immunosuppressive therapy","volume":"83","author":"Chuhjo","year":"2008","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000205048","article-title":"Efficacy of danazol in hematologic disorders","volume":"84","author":"Ahn","year":"1990","journal-title":"Acta Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101132_bb0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/10245332.2018.1435045","article-title":"Danazol increases T regulatory cells in patients with aplastic anemia","volume":"23","author":"Khurana","year":"2018","journal-title":"Hematology."},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0090-1229(87)90016-X","article-title":"Immune modulation by danazol in autoimmune thrombocytopenia","volume":"42","author":"Mylvaganam","year":"1987","journal-title":"Clin Immunol Immunopathol"},{"issue":"9","key":"10.1016\/j.blre.2023.101132_bb0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-111-9-723","article-title":"Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women","volume":"111","author":"Ahn","year":"1989","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.blre.2023.101132_bb0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJM198702263160903","article-title":"Effect of danazol in immune thrombocytopenic purpura","volume":"316","author":"Schreiber","year":"1987","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1096\/fasebj.3.2.2914627","article-title":"Danazol therapy renders red cells resistant to osmotic lysis 1","volume":"3","author":"Ahn","year":"1989","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2141.1996.6322262.x","article-title":"Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy","volume":"94","author":"Hebbar","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0609.1979.tb00430.x","article-title":"Androgen therapy of aplastic Anaemia-a prospective study of 352 cases","volume":"22","author":"Anaemias Secretaries","year":"1979","journal-title":"Scand J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1986.tb01748.x","article-title":"French cooperative group for the study of aplastic and refractory anaemias. Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens","volume":"36","author":"Najean","year":"1986","journal-title":"Scand J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0150","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.V53.3.504.504","article-title":"A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia","volume":"53","author":"Camitta","year":"1979","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101132_bb0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0308-2261(21)00051-5","article-title":"For the international aplastic Anaemia study group: severe aplastic anemia; a prospective study of the effect of androgens or transplantation on haematological recovery and survival","volume":"7","author":"Camitta","year":"1978","journal-title":"Clin Haematol"},{"key":"10.1016\/j.blre.2023.101132_bb0160","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12185-010-0601-1","article-title":"Clinical course of non-severe aplastic anemia in adults","volume":"91","author":"Kwon","year":"2010","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.1979.tb05865.x","article-title":"Clinical course in 28 unselected patients with aplastic anaemia treated with anabolic steroids","volume":"41","author":"Van Hengstum","year":"1979","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0170","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000208508","article-title":"Androstane therapy of aplastic anaemia","volume":"47","author":"Duarte","year":"1972","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V32.1.83.83","article-title":"Oxymetholone therapy in aplastic anemia","volume":"32","author":"Allen","year":"1968","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood.V34.3.283.283","article-title":"Anabolic androgenic steroids in the treatment of acquired aplastic anemia","volume":"34","author":"La","year":"1969","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101132_bb0185","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.282935","article-title":"Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation","author":"Pagliuca","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0190","first-page":"141","article-title":"Presentation and outcome of 25 cases of Fanconi\u2019s anemia","volume":"11","author":"Rogers","year":"1989","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pbc.24617","article-title":"Oxandrolone for the treatment of bone marrow failure in Fanconi anemia","volume":"61","author":"Rose","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.blre.2023.101132_bb0200","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0205","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3324\/haematol.2022.281808","article-title":"Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial","volume":"108","author":"Cl\u00e9","year":"2023","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/08880018.2015.1129567","article-title":"Androgen therapy in Fanconi anemia: a retrospective analysis of 30 years in Germany","volume":"33","author":"Paustian","year":"2016","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101132_bb0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MPH.0000000000001549","article-title":"Bone marrow failure in fanconi anemia: clinical and genetic spectrum in a cohort of 20 pediatric patients","volume":"41","author":"Kelaidi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0220","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjh.16445","article-title":"Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian inherited marrow failure registry","volume":"189","author":"Catal\u00e0","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0225","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bcmd.2011.11.006","article-title":"Treatment of the bone marrow failure in Fanconi anemia patients with danazol","volume":"48","author":"Scheckenbach","year":"2012","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.12748","article-title":"Response to androgen therapy in patients with dyskeratosis congenita","volume":"165","author":"Khincha","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0235","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.16997","article-title":"Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita","volume":"193","author":"Kirschner","year":"2021","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.blre.2023.101132_bb0240","first-page":"1615","article-title":"Clonal hematopoiesis in the inherited bone marrow failure syndromes","volume":"136","author":"Tsai","year":"2020","journal-title":"Blood."},{"issue":"3\u20134","key":"10.1016\/j.blre.2023.101132_bb0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.beha.2014.10.002","article-title":"Fanconi anemia and the development of leukemia","volume":"27","author":"Alter","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"110","key":"10.1016\/j.blre.2023.101132_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"5","author":"Duchmann","year":"2019","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101132_bb0255","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1634\/theoncologist.12-10-1264","article-title":"Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis","volume":"12","author":"Ross","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0260","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2023.101132_bb0265","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0270","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bjh.13088","article-title":"Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials","volume":"167","author":"Prica","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101132_bb0275","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41375-021-01190-9","article-title":"Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia","volume":"35","author":"Fattizzo","year":"2021","journal-title":"Leukemia."},{"issue":"94","key":"10.1016\/j.blre.2023.101132_bb0280","article-title":"Anabolic steroids in myelodysplastic syndromes: a systematic review","volume":"22","author":"Garcia-Horton","year":"2020","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/1097-0142(19950101)75:1<133::AID-CNCR2820750124>3.0.CO;2-I","article-title":"A review of 76 patients with myelodysplastic syndromes treated with danazol","volume":"75","author":"Avil\u00e9s","year":"1995","journal-title":"Cancer."},{"issue":"12","key":"10.1016\/j.blre.2023.101132_bb0290","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/1097-0142(19940615)73:12<3073::AID-CNCR2820731228>3.0.CO;2-#","article-title":"A review of 76 patients with myelodysplastic syndromes treated with danazol","volume":"73","author":"Chabannon","year":"1994","journal-title":"Cancer."},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0295","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1987.tb00780.x","article-title":"Danazol in the treatment of myelodysplastic syndromes","volume":"39","author":"Buzaid","year":"1987","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0300","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000058321","article-title":"Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes","volume":"107","author":"Viniou","year":"2002","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0305","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2141.1991.tb08617.x","article-title":"Danazol treatment of myelodysplastic syndromes","volume":"77","author":"Stadtmauer","year":"1991","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0310","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000867","article-title":"Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an \u201cOld-fashioned\u201d Drug be Effective?","volume":"7","author":"Riva","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.1994.tb04895.x","article-title":"Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases","volume":"87","author":"Wattel","year":"1994","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0320","first-page":"103","article-title":"Androgen in the treatment of refractory anemia","volume":"54","author":"Kobaba","year":"1991","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0325","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/bjh.16121","article-title":"Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study","volume":"187","author":"Choi","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0335","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1993.tb08686.x","article-title":"Refractory anaemia (RA) type I FAB treated with oxymetholone (OXY): long-term results","volume":"85","author":"Rafael Hurtado","year":"1993","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101132_bb0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/0277-5379(88)90339-2","article-title":"Therapeutic efficacy of danazol in myelodysplastic syndromes","volume":"24","author":"Marini","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0345","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clml.2017.11.007","article-title":"Danazol as first-line therapy for myelodysplastic syndrome","volume":"18","author":"Colunga-Pedraza","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.1991.tb01555.x","article-title":"Danazol: in vitro effects on human hemopoiesis and in vivo activity in hypoplastic and myelodysplastic disorders","volume":"47","author":"Selleri","year":"1991","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0355","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ajh.2830230409","article-title":"Efficacy of danazol in pure red cell aplasia","volume":"23","author":"Lippman","year":"1986","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0360","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-103-1-58","article-title":"Danazol therapy in myelodysplasia","volume":"103","author":"Db","year":"1985","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0365","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000205984","article-title":"Danazol therapy in acquired idiopathic sideroblastic anemia","volume":"77","author":"Doll","year":"1987","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0370","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.10209","article-title":"Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome","volume":"71","author":"Chan","year":"2002","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101132_bb0375","first-page":"1703","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood, J American Soc Hematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101132_bb0380","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2021.1944096","article-title":"Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions","volume":"14","author":"Yoon","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101132_bb0385","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"Hemasphere."},{"issue":"8","key":"10.1016\/j.blre.2023.101132_bb0390","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.1982.00340210131023","article-title":"Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only","volume":"142","author":"Brubaker","year":"1982","journal-title":"Arch Intern Med"},{"issue":"10373","key":"10.1016\/j.blre.2023.101132_bb0395","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2023.101132_bb0400","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0405","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4","article-title":"Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival","volume":"49","author":"Besa","year":"1982","journal-title":"Cancer."},{"issue":"8","key":"10.1016\/j.blre.2023.101132_bb0410","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1056\/NEJM196602242740802","article-title":"Androgens and erythropoiesis: further evaluation of testosterone treatment of myelofibrosis","volume":"274","author":"Gardner","year":"1966","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0415","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jama.1962.03050410012003","article-title":"Effect of androgenic hormone in myelofibrosis","volume":"182","author":"Kennedy","year":"1962","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0420","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1096-8652(199602)51:2<112::AID-AJH3>3.0.CO;2-0","article-title":"Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases","volume":"51","author":"Kolodny","year":"1996","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101132_bb0430","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41375-020-0950-6","article-title":"High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag","volume":"35","author":"Hosokawa","year":"2021","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0435","doi-asserted-by":"crossref","first-page":"2224044","DOI":"10.1080\/07853890.2023.2224044","article-title":"Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory\/relapsed\/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial","volume":"55","author":"Wan","year":"2023","journal-title":"Ann Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101132_bb0440","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41409-020-0897-2","volume":"55","author":"ElGohary","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101132_bb0445","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/bmt.2016.347","article-title":"Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results","volume":"52","author":"Liu","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101132_bb0450","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2012.252","article-title":"Cord blood transplantation in aplastic anemia","volume":"48","author":"Peffault de Latour","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"10399","key":"10.1016\/j.blre.2023.101132_bb0455","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"The Lancet"},{"issue":"3\u20134","key":"10.1016\/j.blre.2023.101132_bb0460","first-page":"97","article-title":"Therapeutic options in high-risk myelodysplastic syndrome","volume":"13","author":"Maksymowicz","year":"2022","journal-title":"Hematol Clin Pract"},{"issue":"1","key":"10.1016\/j.blre.2023.101132_bb0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion\u2013burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101132_bb0470","series-title":"Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study","first-page":"7016-7016","author":"Gerds","year":"2023"},{"issue":"138","key":"10.1016\/j.blre.2023.101132_bb0475","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2021-150908","article-title":"Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis","volume":"23","author":"Bose","year":"2021","journal-title":"Blood."},{"issue":"136","key":"10.1016\/j.blre.2023.101132_bb0480","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-140364","article-title":"Ker-050, a novel inhibitor of Tgf\u03b2 superfamily signaling, induces red blood cell production by promoting multiple stages of erythroid differentiation","volume":"5","author":"Feigenson","year":"2020","journal-title":"Blood."},{"issue":"136","key":"10.1016\/j.blre.2023.101132_bb0485","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134574","article-title":"A phase 1\/2 study of INCB000928 as monotherapy or in combination with ruxolitinib in patients with anemia due to myelofibrosis (INCB 00928-104)","volume":"5","author":"Oh","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101132_bb0490","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02031976","article-title":"Danazol induced pancreatitis and hepatitis","volume":"9","author":"Chevalier","year":"1990","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.blre.2023.101132_bb0495","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/oxfordjournals.humrep.a138651","article-title":"Acute pancreatitis associated with danazol treatment for endometriosis","volume":"9","author":"Balasch","year":"1994","journal-title":"Hum Reprod"},{"issue":"7","key":"10.1016\/j.blre.2023.101132_bb0500","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0149-2918(08)80058-6","article-title":"Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg\/d and lovastatin 40 mg\/d","volume":"30","author":"Hsieh","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.blre.2023.101132_bb0505","first-page":"1","article-title":"2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema","volume":"6","author":"Bowen","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"12","key":"10.1016\/j.blre.2023.101132_bb0510","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","article-title":"Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema","volume":"30","author":"Birjmohun","year":"2008","journal-title":"Clin Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:33:05Z","timestamp":1759437185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":102,"alternative-id":["S0268960X23000930"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101132","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101132"}}